Marie Hudson , Yves Troyanov , Océane Landon-Cardinal
{"title":"Scleromyositis – The new frontier","authors":"Marie Hudson , Yves Troyanov , Océane Landon-Cardinal","doi":"10.1016/j.berh.2026.102126","DOIUrl":null,"url":null,"abstract":"<div><div>In this review, we examine the clinical, serological, and pathological characteristics of muscle involvement in systemic sclerosis (SSc) and delineate features that distinguish it from other autoimmune myositis (AIM). We posit that muscle involvement in SSc represents a primary disease manifestation rather than an overlap between two conditions, reflecting shared pathogenic mechanisms with other organ manifestations in SSc. On this basis, we propose the term scleromyositis (SM). We further propose a conceptual framework for the pathogenesis of SM, review current knowledge on its prognosis and management, and present illustrative cases that highlight features that are unique to this entity. We aim to increase awareness of this under-recognized entity, highlight its broad spectrum and encourage a more consistent use of the term scleromyositis.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"40 2","pages":"Article 102126"},"PeriodicalIF":7.0000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research in Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521694226000112","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In this review, we examine the clinical, serological, and pathological characteristics of muscle involvement in systemic sclerosis (SSc) and delineate features that distinguish it from other autoimmune myositis (AIM). We posit that muscle involvement in SSc represents a primary disease manifestation rather than an overlap between two conditions, reflecting shared pathogenic mechanisms with other organ manifestations in SSc. On this basis, we propose the term scleromyositis (SM). We further propose a conceptual framework for the pathogenesis of SM, review current knowledge on its prognosis and management, and present illustrative cases that highlight features that are unique to this entity. We aim to increase awareness of this under-recognized entity, highlight its broad spectrum and encourage a more consistent use of the term scleromyositis.
期刊介绍:
Evidence-based updates of best clinical practice across the spectrum of musculoskeletal conditions.
Best Practice & Research: Clinical Rheumatology keeps the clinician or trainee informed of the latest developments and current recommended practice in the rapidly advancing fields of musculoskeletal conditions and science.
The series provides a continuous update of current clinical practice. It is a topical serial publication that covers the spectrum of musculoskeletal conditions in a 4-year cycle. Each topic-based issue contains around 200 pages of practical, evidence-based review articles, which integrate the results from the latest original research with current clinical practice and thinking to provide a continuous update.
Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. The review articles seek to address the clinical issues of diagnosis, treatment and patient management. Management is described in practical terms so that it can be applied to the individual patient. The serial is aimed at the physician in both practice and training.